Sinus Node Dysfunction — Bradycardia

The sinoatrial (SA) node is the primary pacemaker of the heart, located subepicardially at the junction of the superior vena cava and the right atrium, along the sulcus terminalis. It is a crescent-shaped structure approximately 13–20 mm in length and 2–3 mm in thickness, composed of specialized pacemaker cells (P cells) embedded in a dense connective tissue matrix. The SA node artery, which arises from the right coronary artery in approximately 55–60% of patients and from the left circumflex artery in 40–45%, courses through or around the node and is critical to its function.

SA node automaticity depends on the spontaneous phase 4 diastolic depolarization of P cells. The funny current (I_f), carried primarily through HCN4 channels, initiates the slow diastolic depolarization. This is augmented by the calcium clock mechanism — spontaneous sarcoplasmic reticulum calcium release activating the Na⁺/Ca²⁺ exchanger (NCX), generating an inward depolarizing current. The upstroke of the SA node action potential is mediated by L-type calcium channels (I_Ca,L) rather than fast sodium channels, which accounts for the relatively slow conduction velocity within the node.

Sinus node dysfunction (SND) encompasses a spectrum of disorders resulting from impaired impulse formation by the SA node, impaired conduction from the SA node to the surrounding atrial myocardium, or both. The clinical manifestations depend on which aspect of SA node function is compromised.

Intrinsic vs Extrinsic SND

Intrinsic SND results from structural or functional abnormalities of the SA node itself. The most common cause is age-related idiopathic fibrosis of the SA node and perinodal tissue, with progressive replacement of pacemaker cells by fibrous tissue. Other intrinsic causes include ischemic heart disease (particularly right coronary artery disease), infiltrative cardiomyopathies (amyloidosis, sarcoidosis, hemochromatosis), inflammatory conditions (myocarditis, pericarditis, rheumatic heart disease), and inherited channelopathies (SCN5A mutations, HCN4 mutations).

Extrinsic SND results from factors outside the SA node that suppress its function. These include enhanced vagal tone (athletes, vasovagal syncope), medications (beta-blockers, calcium channel blockers, digoxin, antiarrhythmics, lithium), electrolyte abnormalities (hyperkalemia, hypothyroidism), obstructive sleep apnea, and increased intracranial pressure. Extrinsic causes are frequently reversible and must be excluded before attributing SND to an intrinsic process.

Clinical Subtypes

Sinus bradycardia (heart rate <50 bpm) is the most common manifestation but is only clinically significant when it produces symptoms. Sinus arrest represents a failure of impulse generation, resulting in absent P waves for a duration that is not a multiple of the baseline PP interval. Sinoatrial exit block occurs when the SA node fires normally but the impulse fails to conduct to the surrounding atrial tissue — analogous to AV block but at the SA node level. Chronotropic incompetence is the inability to achieve 80% of age-predicted maximum heart rate (220 − age) during exercise — this is the most common manifestation of SND in some series and may be the earliest sign of SA node disease.

The tachycardia-bradycardia syndrome (tachy-brady syndrome) is characterized by alternating episodes of atrial tachyarrhythmias (typically atrial fibrillation or atrial flutter) and symptomatic bradycardia. The prolonged pauses following termination of tachycardia episodes result from overdrive suppression of the dysfunctional SA node. This syndrome affects approximately 50% of patients with SND and often necessitates both rhythm control (or rate control) and pacing.

Post-Surgical SND

SND is a well-recognized complication following congenital heart surgery, particularly operations involving extensive atrial suture lines. The Fontan procedure, Mustard/Senning operations (atrial switch for d-TGA), and Glenn shunt are associated with high rates of SND due to direct injury to the SA node or its arterial supply, disruption of perinodal conduction pathways, and atrial scarring. In the current era of the arterial switch operation for d-TGA, SND rates have decreased substantially compared with the atrial switch.

The surface ECG and continuous telemetry monitoring are the primary diagnostic tools for SND. While a single resting 12-lead ECG may appear normal between symptomatic episodes, ambulatory monitoring (Holter, event recorder, implantable loop recorder) frequently captures the diagnostic arrhythmia. The key is establishing symptom–rhythm correlation — demonstrating that the patient's symptoms (presyncope, syncope, fatigue, exercise intolerance) occur simultaneously with documented bradycardia or pauses.

Sinus bradycardia is defined as a sinus rhythm with a rate below 60 bpm, though rates below 50 bpm are generally considered more clinically relevant. Importantly, resting sinus bradycardia as low as 40 bpm can be physiologic in well-trained athletes and during sleep, and does not by itself indicate SND.

Sinus pauses are defined as the absence of P wave activity for a duration exceeding the baseline PP interval. Pauses greater than 3 seconds during waking hours are generally considered abnormal, though pauses up to 2–3 seconds can occur during sleep in normal individuals. Pauses exceeding 5–6 seconds are associated with syncope and are a Class I indication for permanent pacing in the setting of symptoms.

Sinoatrial exit block is analogous to AV block but occurs at the SA-atrial junction. It is classified as first-degree (prolonged SA conduction time, not visible on surface ECG), second-degree (intermittent failure of SA impulse conduction), and third-degree (complete failure of SA impulse conduction). Second-degree SA exit block is further subdivided into Mobitz type I (Wenckebach) and Mobitz type II patterns.

Junctional escape rhythms at rates of 40–60 bpm may emerge during prolonged sinus pauses or sinus arrest, indicating intact subsidiary pacemaker function. The absence of an adequate junctional escape during sinus pauses (escape rate <40 bpm or absent escape) portends a higher risk of syncope and underscores more diffuse conduction system disease.

Tachy-brady transitions are best captured on telemetry or Holter monitoring. The characteristic pattern shows an abrupt termination of atrial fibrillation or flutter followed by a prolonged pause (often >3–5 seconds) before resumption of sinus rhythm or a junctional escape. These pauses often correlate with the patient's most dramatic symptoms — syncope or near-syncope.

Invasive EP testing for SND has a limited role in clinical practice because its sensitivity is modest (50–70%) and clinical decisions are more commonly guided by symptom–rhythm correlation on ambulatory monitoring. However, EP testing can be useful when non-invasive monitoring has failed to establish a diagnosis, or when concurrent evaluation of AV conduction or inducible arrhythmias is needed. Understanding the key EP parameters is essential for the electrophysiology fellow.

Sinus Node Recovery Time (SNRT)

The SNRT is the most widely used EP measure of SA node function. It is measured by pacing the right atrium at progressively faster rates (typically 100, 120, 140, and 150 bpm) for 30–60 seconds at each rate, then abruptly ceasing pacing. The SNRT is the interval from the last paced atrial electrogram to the first spontaneous sinus return beat. Normal SNRT is <1500 ms. The concept is that overdrive pacing suppresses the SA node (overdrive suppression), and a diseased node takes longer to recover automaticity.

The corrected SNRT (cSNRT) is calculated by subtracting the baseline sinus cycle length (SCL) from the SNRT: cSNRT = SNRT − SCL. This corrects for the patient's baseline heart rate. A cSNRT >550 ms is considered abnormal and suggestive of SND. Some laboratories use a cutoff of >525 ms. The cSNRT has a specificity of approximately 90% but a sensitivity of only 50–70%, meaning that a normal cSNRT does not exclude SND.

Secondary pauses following the initial sinus return beat may also be significant. The total recovery time (time until the sinus cycle length stabilizes to within 10% of baseline) and the presence of secondary pauses that exceed the initial SNRT are additional markers of SA node dysfunction.

Sinoatrial Conduction Time (SACT)

The SACT measures the conduction time from the SA node to the surrounding atrial tissue. Since the SA node electrogram is not routinely recorded, the SACT is estimated indirectly. The Strauss method uses premature atrial extrastimuli: a premature atrial beat (A2) is delivered at progressively shorter coupling intervals, and the return cycle (A2–A3) is measured. The SACT is estimated as half the difference between the return cycle and the baseline sinus cycle length: SACT = (A2A3 − A1A1) ÷ 2. Normal SACT is <120 ms. The Narula method uses brief atrial pacing (8 beats) at a rate just above the sinus rate, with the SACT estimated from the post-pacing return cycle. Both methods have significant limitations due to assumptions about SA node entrance and exit block patterns.

Intrinsic Heart Rate Testing

The intrinsic heart rate (IHR) is the SA node firing rate after complete autonomic blockade with intravenous atropine (0.04 mg/kg) and propranolol (0.2 mg/kg). This eliminates sympathetic and parasympathetic influences, revealing the intrinsic pacemaker function. The predicted IHR is calculated by the formula: IHR = 118.1 − (0.57 × age). An observed IHR below the predicted value suggests intrinsic SA node disease, while a normal IHR in the setting of clinical bradycardia suggests extrinsic (autonomically mediated) SND.

Limitations of EP Testing

The EP study for SND has several important limitations. First, it assesses SA node function at a single point in time and may miss intermittent dysfunction. Second, the SNRT and SACT are influenced by sedation, autonomic tone, and the specific pacing protocol used. Third, the sensitivity is insufficient to reliably exclude SND when clinical suspicion is high. For these reasons, the 2018 ACC/AHA/HRS bradycardia guidelines do not recommend routine invasive EP testing for SND diagnosis and instead emphasize prolonged ambulatory monitoring (including implantable loop recorders) for symptom–rhythm correlation. EP testing remains most useful when performed as part of a comprehensive study evaluating AV conduction, His-Purkinje function, and inducible tachyarrhythmias in patients with unexplained syncope.

Permanent pacing is the definitive therapy for symptomatic SND. There is no pharmacologic therapy that reliably and safely increases heart rate on a long-term basis. The decision to implant a permanent pacemaker rests on the correlation of symptoms with documented bradycardia and the exclusion of reversible causes. The 2018 ACC/AHA/HRS guidelines on bradycardia and cardiac conduction delay provide a comprehensive framework for pacing indications.

Guideline Indications (ACC/AHA/HRS 2018)

Class I (Recommended):

• SND with documented symptomatic bradycardia, including frequent sinus pauses that produce symptoms (Level of Evidence: C-LD)
• Symptomatic chronotropic incompetence (Level of Evidence: C-LD)
• SND with symptomatic bradycardia resulting from required drug therapy for which there is no acceptable alternative (Level of Evidence: C-LD)

Class IIa (Reasonable):

• SND with heart rate <40 bpm when a clear association between significant symptoms consistent with bradycardia and the actual presence of bradycardia has not been documented (Level of Evidence: C-EO)
• Syncope of unexplained origin when clinically significant SND is discovered or provoked during EP study (Level of Evidence: C-LD)

Class IIb (May Be Considered):

• Minimally symptomatic patients with chronic heart rate <40 bpm while awake (Level of Evidence: C-EO)

Class III (Not Indicated):

• SND in asymptomatic patients, including those with heart rates <40 bpm as a consequence of long-term drug therapy
• SND in which symptoms suggestive of bradycardia are clearly documented to occur in the absence of bradycardia
• SND with symptomatic bradycardia due to nonessential drug therapy that can be safely withdrawn

Pacing Mode Selection

Single-chamber atrial pacing (AAI/AAIR) was historically considered the most physiologic mode for isolated SND with intact AV conduction. The DANPACE trial demonstrated that AAIR pacing was associated with a higher rate of paroxysmal atrial fibrillation and a 1.9% annual rate of pacemaker upgrade for AV block compared with DDDR pacing. For this reason, AAI/AAIR pacing is now less commonly used in clinical practice.

Dual-chamber pacing (DDD/DDDR) is the most widely used mode for SND. It preserves AV synchrony and provides backup ventricular pacing in the event of concomitant or future AV conduction disease, which develops in 2–3% of SND patients per year. The landmark MOST trial (Mode Selection Trial) randomized 2010 patients with SND to DDDR versus VVIR pacing and found no difference in all-cause mortality or heart failure hospitalization, but DDDR pacing was associated with a significant reduction in atrial fibrillation (hazard ratio 0.79) and a lower incidence of the pacemaker syndrome.

Single-chamber ventricular pacing (VVI/VVIR) is generally avoided in SND patients with intact AV conduction because loss of AV synchrony leads to pacemaker syndrome (hypotension, fatigue, dyspnea, cannon A waves) in up to 20–25% of patients. VVI pacing may be considered in patients with permanent atrial fibrillation where atrial pacing offers no benefit.

Minimizing Unnecessary RV Pacing

A critical consideration in SND pacing is minimizing right ventricular pacing, which can cause ventricular dyssynchrony and, over time, pacing-induced cardiomyopathy. The DAVID trial demonstrated that dual-chamber pacing with a high percentage of RV pacing (DDDR at 70 bpm) was associated with increased heart failure and mortality compared with VVI backup pacing (40 bpm) in patients with LV dysfunction. Modern pacemakers incorporate managed ventricular pacing (MVP) algorithms (Medtronic), SafeR (ELA/Sorin), and similar features that operate in an AAI(R) mode with automatic switching to DDD(R) only when AV block is detected. These algorithms reduce unnecessary RV pacing to <5% in most SND patients and are now standard programming for SND indications.

Rate-Responsive Pacing

Rate-responsive pacing (designated by the “R” in DDDR or AAIR) is essential for SND patients with chronotropic incompetence. Rate-responsive sensors detect physiologic demand for increased heart rate and adjust the pacing rate accordingly. The most common sensors are accelerometer-based (detecting body motion/vibration) and minute ventilation (measuring transthoracic impedance changes with respiration). Some devices use blended sensors that combine both for more physiologic rate response. Programming considerations include setting an appropriate maximum sensor rate (typically 120–130 bpm in elderly patients, higher in younger active patients), activity threshold, and response time. An exercise test with telemetry monitoring of the paced rate is invaluable for optimizing sensor settings.

Leadless Pacing

Leadless pacemaker technology (Micra, Abbott AVEIR) has expanded options for SND patients, though with important limitations. The Micra AV single-chamber leadless pacemaker uses an accelerometer to detect atrial mechanical contraction and provide AV-synchronized ventricular pacing (VDD-like mode) without an atrial lead. However, it cannot provide atrial pacing. The AVEIR DR system (Abbott) is the first dual-chamber leadless pacing system, using two communicating leadless devices (one atrial, one ventricular) to provide true DDD pacing without transvenous leads. Leadless pacing is particularly attractive for patients at high risk of lead-related complications (prior lead infection, difficult venous access, dialysis patients), though long-term data are still accumulating.